MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
about
Alum: an old dog with new tricksUse of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in miceEffect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccineUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinA caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goatsAssessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.New vaccines against influenza virus.Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in miceImmunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenImmunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge.Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.Safety and immunogenicity of a candidate parvovirus B19 vaccineImmunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogensEffects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.Adjuvanted influenza vaccines.Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral ReseA physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.A multi-criteria decision making approach to identify a vaccine formulation.
P2860
Q26752643-939A4587-8055-4BA4-BFF8-DA025C7DB131Q27304934-B5ED595B-E87E-40E0-B9A5-0138C1DC9316Q28728791-51970837-C293-406B-8373-54EB52386D2BQ28730561-4A2246BD-1DDD-4CA4-960A-576880AEDB16Q28730610-23C7FF06-3FC2-455A-85A3-83D7B0B9E69EQ30223941-271DD508-4FFB-42AC-8C92-88CFB1D5B657Q30352329-222B5F7D-73C6-42F6-B1BB-BA2232CA2407Q30357932-5DBB5EC1-B93F-4783-BFE5-B50AADC619F1Q30370790-FB3E0E05-3448-4D9E-A69C-957C698BBF77Q30371111-45A42018-0E0D-4CFD-B242-848AF6B7A80FQ30404358-BB01A9BB-A6CB-47E8-BFB7-21AC6336B5C2Q34290857-8F34AEC8-EB60-4054-A130-37EAD17B30D3Q34869353-EC4D9BD8-9AC7-4CC1-A183-0B01FE3A8A0FQ35268947-F426C7BB-A9DA-4343-9B84-645C591BB7CBQ35887679-E4A9B0D4-C4FC-4927-8B9F-92FB44EFDD10Q36500269-21810753-2369-4288-9B4D-C553C819BE97Q37093487-E6416C5D-8BBC-47CE-851E-CED5AF65DE84Q37857249-960D46CF-1B5C-4C4D-944C-F0D204F6389DQ38140045-15825C94-7992-4C12-90B2-A3A950CDDDC1Q38947443-9423324F-E33D-4A87-A777-A7CD42F10E0EQ39373123-5E60716F-B7B9-4A10-90CF-F0C2EED9B47EQ39539750-9B6F1769-FDA1-4E32-A02A-F7711FEF6829Q41534119-C5C49C7F-5E0E-4B2F-8472-902B6E1C473C
P2860
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@ast
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@en
type
label
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@ast
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@en
prefLabel
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@ast
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@en
P2860
P356
P1476
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
@en
P2093
Hana El Sahly
P2860
P304
P356
10.1586/ERV.10.111
P577
2010-10-01T00:00:00Z